http://archinte.jamanetwork.com/ en-us Tue, 01 Mar 2011 00:00:00 GMT Tue, 01 Jan 2013 00:49:07 GMT Silverchair editor@archinte.jamanetwork.com webmaster@archinte.jamanetwork.com http://archinte.jamanetwork.com/article.aspx?articleID=486411 Mon, 28 Feb 2005 00:00:00 GMT Rosiñol L, Montoto S, Cibeira M, et al. <span class="paragraphSection">Bortezomib is a novel proteasome inhibitor with significant antimyeloma activity. Its toxicity is manageable, and the most frequent adverse effects mainly consist of gastrointestinal symptoms, peripheral neuropathy, neuropatic pain, and thrombocytopenia. Severe liver toxicity has not been previously recognized. A patient with relapsed multiple myeloma who developed bortezomib-induced severe recurrent hepatitis is described. The importance of recognizing this rare potential toxicity is highlighted in order to discontinue this agent if liver adverse reaction is suspected.</span> 165 4 464 465 10.1001/archinte.165.4.464 http://archinte.jamanetwork.com/article.aspx?articleID=486411